COVID-19 after rituximab therapy in cSLE patients
Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who...
Main Authors: | Meghan Corrigan Nelson, Cynthia K. Manos, Elaine Flanagan, Sampath Prahalad |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-06-01
|
Series: | Therapeutic Advances in Vaccines and Immunotherapy |
Online Access: | https://doi.org/10.1177/25151355231181242 |
Similar Items
-
Childhood-onset systemic lupus erythematosus (cSLE) and malignancy: a nationwide multicentre series review
by: Matheus Zanata Brufatto, et al.
Published: (2024-02-01) -
Presentation of SLE after COVID vaccination in a pediatric patient
by: Meghan Corrigan Nelson, et al.
Published: (2022-12-01) -
SLE‐associated myelitis successfully treated by rituximab
by: Alireza Khabbazi, et al.
Published: (2022-11-01) -
Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis
by: Meghan Corrigan Nelson DO, et al.
Published: (2023-09-01) -
Expression of the miR-9-5p, miR-125b-5p and its target gene NFKB1 and TRAF6 in childhood-onset systemic lupus erythematosus (cSLE)
by: Denise de Queiroga Nascimento, et al.
Published: (2022-11-01)